Weight loss and lifestyle changes have proven to be effective in restoring menstrual regularity and reproductive function, improving hyperandrogenism, glucose and lipid metabolism, and insulin sensitivity, thus reducing cardiovascular risk in women with PCOS [18,19,20]
Boosts energy production and enhances endurance
Global GLP-1 Receptor Agonist Market Recent Developments: 2025: Eli Lilly's once-daily oral GLP-1 agonist Orforglipron completed Phase III trials, delivering meaningful weight loss and strong blood-glucose (A1C) reduction
It helps to improve the safety and reliability of experimental results
This means, while patients may lose some lean body and muscle mass, weight loss likely results in an increase in muscle quality
Interleukin 17 Regulates SHP-2 and IL-17ra/STAT-3 Dependent Cyr61, IL-23 and GM-CSF Expression and RANKL Mediated Osteoclastogenesis by Fibroblast-Like Synoviocytes in Rheumatoid Arthritis